Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lexicon Pharmaceuticals (New Jersey) Inc.

Division of Lexicon Pharmaceuticals Inc.

Latest From Lexicon Pharmaceuticals (New Jersey) Inc.

Chemistry Models

Given the large number of targets pharma companies must now screen and for which they must find small-molecule ligands, are venture funds currently looking to invest in new chemistry technologies that could help? Yes--but one big problem is the business model.
BioPharmaceutical Strategy


Despite the in silico research ideals of many genomicists, no one has yet found a way around the basic requirement for using human tissue in gene expression studies-a broad array of it, well characterized, from healthy and diseased patients, and from world populations at large. That's why start-ups, drug discovery firms and others are creating a new resource: biorepositories--banks of tissue samples and data to serve the diagnostic, pharmaceutical and tissue engineering industries. As providers of services and products to research-based companies, these companies believe they are operating in a market that ranges from $500 million to $5 billion.
BioPharmaceutical Business Strategies

Chemistry Firms Still Second Fiddle in Biology-Chemistry Mergers

With a scarcity of well-trained chemists and exponentially increasing numbers of genomics-generated targets contributing to an already bulging lead identification/optimization bottleneck, medicinal chemistry capabilities are at a premium. Nonetheless, when it comes to market valuations, biology companies still come out on top. And Celera's recent acquisition of Axys, along with Lexicon Genetics purchase of Coelacanth help prove the point.
BioPharmaceutical Strategy

ArQule Takes the Drug Discovery Plunge

Over the past two-and-one-half years, ArQule's new management has refocused the once divided company, and repaired its reputation in the eyes of the financial community. That leadership also decided that ArQule can reach its growth potential only by moving away from a fee-for-services model and becoming a full-fledged drug discovery company. It's a transition that few companies have successfully managed, in part because of the tough balancing act required to build the requisite R&D infrastructure, while devoting sufficient resources to the near-term activity needed to build that infrastructure. ArQule will likely try to acquire biology-based companies to gain control over its own targets, but must deal with the valuation imbalance that still favors genomics/biology firms. But ArQule's management believes that its technology platform--as enhanced by the addition of predictive ADMET modeling--will boost its ability to process target into targets and thus its value.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Coelacanth Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Lexicon Pharmaceuticals Inc.
  • Senior Management
  • John Skolas, CFO
    David Kimball, PhD, Sr. Dir., Medicinal Chemistry
    Tamar D Howson, EVP, Bus. Dev.
  • Contact Info
  • Lexicon Pharmaceuticals (New Jersey) Inc.
    Phone: (609) 466-5590
    350 Carter Rd.
    Princeton, NJ 08540